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In vitro assayAnthelmintic resistance has emerged as an important problem in animal industries. Understanding resis-
tance mechanisms, especially against macrocyclic lactones (MLs), is the ﬁrst step in developing better
diagnostic tools. Effects of several MLs including ivermectins and milbemycins were tested using two
well established in vitro assays: the larval development assay (LDA) and the larval migration inhibition
assay (LMIA). These were performed on free-living stages of susceptible and ML-resistant isolates of three
trichostrongyloid nematode species of sheep. In general, dose response curves shifted to the right in the
resistant isolates. Data showed that resistance was present to ivermectin and its two components sug-
gesting that both components contribute to action and resistance. There were no consistent patterns
of potency and resistance of the tested substances for the different isolates in the LDA except that moxi-
dectin (MOX) tended to have lower resistance ratios than ivermectin (IVM). MOX was the most potent
inhibitor in the LMIA in susceptible Haemonchus contortus while being less potent in Trichostrongylus
colubriformis and particularly in Ostertagia circumcincta. MOX showed high resistance ratios in the LMIA
in all three species. Based on these results, resistance to MOX has unique characteristics and the LMIA
may perform better in detecting resistance to MOX in these parasite species.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
The macrocyclic lactone anthelmintics (MLs), typiﬁed by iver-
mectin (IVM) have become the mainstay of control of internal par-
asites of sheep and other production animals. However, the
development of anthelmintic resistance to MLs in several nema-
tode species limits the continued use of these anthelmintics. Resis-
tance to IVM associated with reduced treatment efﬁcacy in
infected animals in the ﬁeld has been reported for Haemonchus
contortus, Trichostrongylus colubriformis and Ostertagia circumcincta
(syn. Teladorsagia circumcincta) in several countries worldwide
(Jackson and Coop, 2000; Le Jambre et al., 2000; Leathwick et al.,
2001; Love, 2002; Kaplan, 2004). ML anthelmintics fall into two
broad classes, the avermectins, including IVM and abamectin
(ABA), and the milbemycins, including moxidectin (MOX). Theydiffer in potency and, possibly, in their resistance proﬁle and phar-
macology (Sutherland et al., 1999; Ardelli et al., 2009; Demeler
et al., 2010). MOX in particular has prolonged clearance kinetics
in vivo which also contributes to its efﬁcacy (see Prichard et al.,
2012 for summary). IVM itself is composed of approximately 80%
of the IVM B1a component and 20% IVM B1b.
In vitro assays have been used to measure the characteristics of
resistance in parasite populations. Such assays are cheap, relatively
quick, obviate host inﬂuences and, as they can be performed over a
concentration range, provide reproducible parameters with which
to measure resistance. Furthermore, they can be used to investi-
gate the mode of action of anthelmintics, the pharmacology of
anthelmintics and the basis of resistance in worms. In vitro tests
also have utility as ﬁeld diagnostic tools and some test systems
have been validated where parasite populations resistant to IVM
treatment in vivo have been found to be less sensitive to IVM in lar-
val development and larval motility assays (Gill et al., 1991, 1995).
IVM is known to inhibit development and motility in larval
stages of gastrointestinal nematodes (Gill et al., 1995). The pharynx
of a number of nematodes has been found to be extremely sensi-
tive to this drug (Geary et al., 1993; Brownlee et al., 1997; Dent
et al., 1997; Kotze, 1998; Sheriff et al., 2002) and it has been
suggested as a major site of action (Geary et al., 1993). The
110 J. Demeler et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 109–118concentrations of IVM required to inhibit pharyngeal pumping in
adults (Sheriff et al., 2002) are similar to the concentrations that in-
hibit larval development in vitro such as in the larval development
assay (LDA) (Gill et al., 1995). Somatic muscle has also been iden-
tiﬁed as a site of action of the ML class. IVM has inhibitory effects
on larvae (Gill et al., 1995; Kotze et al., 2006) and adult worms
(Geary et al., 1993; Kotze et al., 2012). The potency at this site
ranges between 0.015 and 100 nM depending on the method used
to detect motility. Therefore, it can be assumed that the larval
migration inhibition assay (LMIA) can be used to detect effects
on somatic muscle and related neuromuscular sites (Sangster
et al., 1988). On the other hand, the LDA is not speciﬁc for a partic-
ular organ and may involve pharyngeal and/or somatic muscle.
The aim of the present study was to characterise responses to
MLs in resistant and susceptible isolates of three species of sheep
parasitic nematodes and to evaluate possible differences between
several chemical variants of both classes that comprise the anthel-
mintic MLs. In particular, we compared results from the two
in vitro assays. Additional aspects of these experiments were to
evaluate these in vitro test systems as indicators of the in vivo drug
resistance pattern and therefore as diagnostic tools.2. Materials and methods
2.1. Parasites
The H. contortus McMaster isolate (H.c. McM), the T. colubrifor-
mis McMaster (T.c. McM) and the O. circumcincta McMaster isolate
(O.c. McM) were obtained from the McMaster laboratories, CSIRO
(Commonwealth Scientiﬁc and Industrial Research Organisation,
Armidale, Australia). They are all drug susceptible isolates with
no history of exposure to MLs or other anthelmintics.
The H. contortus CAVR (Chiswick-AVermectin-Resistant) is
highly resistant against IVM and avermectins and showed slightly
decreased sensitivity to MOX in vivo (Le Jambre et al., 1995). The
MOXidectin-Resistant isolate of T. colubriformis (T.c. MOX-R) was
originally isolated from a goat farm on the North Coast, NSW,
Australia, where goats had been treated with MOX eight times
per year after IVM failed to remove the parasites. In a controlled
test T.c. MOX-R were found to be resistant to a recommended dose
of MOX (41% efﬁcacy) and ABA (14% efﬁcacy) (Le Jambre et al.,
2005). Both isolates were also obtained from CSIRO. The resistant
isolate O. circumcincta WAMIRO (Western-Australia-Moxidectin-
Resistant Ostertagia) was obtained from Dr. Brown Besier
(WA Department of Agriculture). This MOX-resistant isolate was
originally isolated from sheep at Murdoch University, Australia,
and was cultured without further selection. Use of FECRTs and
slaughter trials showed it to be MOX-resistant (5% efﬁcacy) and
highly IVM-resistant (0% efﬁcacy) (Besier, pers. comm.).
Each isolate was individually passaged every 2 months in
3–9 month old merino-cross wethers. Sheep carrying the resistant
isolate of H. contortus were treated with IVM (0.2 mg/kg), sheep
carrying the resistant isolates of T. colubriformis or O. circumcincta
were treated with MOX (0.2 mg/kg) on each passage, 3 weeks after
infection. Eggs and larvae obtained from at least three different
passages of each isolate were used in the assays. No differences
in response to the tested substances in either assay were observed
for different parasitic stages obtained from different passages.2.2. Materials
IVM was obtained from Sigma (Australia). IVM B1a, IVM B1b,
milbemycin (Mil) A3 and A4 were supplied by the Microbial
Screening Technologies (MST, Smithﬁeld, Australia), MOX was
supplied by Fort Dodge Animal Health (Sydney) as a 95% purepreparation. Stock dilutions of each of the six drugs
(102 M = 10 mM) were prepared in 100% dimethyl sulfoxide
(DMSO). For the LDA these were serially diluted 1:2 with DMSO
to give 12 concentrations. Each were then diluted 1:5 with water
(20% DMSO). Aliquots (10 ll) of each drug concentration were dis-
pensed across the 12 wells of a 96-well-plate (Falcon). Each of the
six compounds occupied one row and the others contained water
with 0.5% DMSO (row A) or 20% DMSO (row H) as controls.
190 ll of molten agar (2%) was added to each well (0.5% ﬁnal
DMSO concentration) and the following ranges of ﬁnal drug con-
centrations: IVM, its components and MOX: 250–0.122 nM; milb-
emycins: 500–0.244 nM.
For the LMIA, the stock solutions were diluted in distiled water
to give ﬁve ﬁnal concentrations each in 1% DMSO. For the resistant
isolates, the concentration range was between 3 lM and 30 nM
and for the susceptible isolates between 1 lM and 10 nM. Appro-
priate concentration ranges for each isolate were determined in
preliminary studies.
2.3. Larval development assay (LDA)
The sensitivity of the isolates was determined in a LDA as de-
scribed by Gill et al. (1995). It measures the potency of anthelmin-
tics as inhibitors of the development of trichostrongyloid
nematodes from eggs though to infective third stage larvae (L3).
Brieﬂy, nematode eggs (80–100/10 ll) recovered from faeces
were added to the surface of an agar matrix in each well of a 96-
well plate. Eggs in these wells were supplemented with nutrient
medium and incubated for 6–8 days at 25 C. A susceptible and a
resistant isolate of the same species were always run in quadrupli-
cate at the same time and a total of three separate assays were per-
formed for each isolate.
The proportion of undeveloped stages [(L1 and L2) + eggs] to the
total (all larvae + eggs) present in each well was calculated and ex-
pressed in percent. Data were corrected for P0, the mean number
of larvae not developing in the control wells. A four parameter lo-
gistic model (GraphPad Prism software) was used to ﬁt sigmoidal
(logistic) curves to the dose–response data and to compare the
curves statistically (using TOP, BOTTOM, EC50, HILLSLOPE as
parameters). A sigmoidal dose response model with variable slope
was chosen to allow ﬁtting of the Hill slope. Positive and negative
control values were deﬁned as 0 and 100 by normalising the con-
trol data to allow exact calculation of the effective concentration
for 50% effect (EC50). Data points from different experiments with
the same drug and isolate were co-analysed and the EC50 and
95% conﬁdence limits were calculated for each isolate. Each EC50
was derived from 288 data points.
For each parasite species, the sensitivity of the resistant isolate
to a given drug was expressed as a resistance ratio (RR) (EC50 for
resistant isolate/EC50 for susceptible isolate). P values, reﬂecting
statistically highly signiﬁcant differences between EC50 values
and the Hill slopes for the resistant and susceptible isolates of each
nematode species for each drug were determined by GraphPad
Prism.
2.4. Larval migration inhibition assay (LMIA)
This assay was carried out similarly to the method described
previously (Sangster et al., 1988; Demeler et al., 2010, 2012); with
some modiﬁcations. Brieﬂy, L3 were incubated in different concen-
trations of drugs and then left to migrate through precision woven
nylon sieves with 25 lm apertures. This size mesh allows active
larvae but not dead larvae to pass through the sieve. Assays were
conducted in 24-well tissue culture plates (Falcon).
L3 were incubated in the drug solutions (1.5 ml) for 24 h in the
dark at 28 C in the plates. A second set of plates (migration plates)
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added to assist counting by keeping the larvae in view under the
microscope. Larvae were then transferred to the 25 lm aperture
sieves in the second plate and allowed to migrate for 24 h at 28 C.
For each concentration, migrated and non-migrated larvae were
counted under a microscope and the percentage of (non-migrated
larvae/total larvae)  100 was calculated. Additionally, postures
and movement characteristics of larvae were noted. The data were
corrected for the average of all control wells from the same plate.
Each assay was carried out in duplicate (on the same plate) and a
total of 2 or 3 assays per isolate and drug were performed.
The data were then analysed using GraphPad Prism software
as for the larval development assay using four to six data points
for each drug concentration. Different experiments with the same
drug and isolate were co-analysed and the EC50, 95% conﬁdence
limits and P values for each isolate were calculated. Each EC50
was derived from 120 data points. The sensitivity of an isolate to
a given drug was expressed as RR.3. Results
3.1. Larval development assay
In the control wells more than 95% of the eggs hatched and
about 95% of the hatched larvae developed through to L3. The
goodness of ﬁt (R2) for all curves was between 0.95 and 0.99.
For H. contortus, the dose–response-curve for all tested compo-
nents (Fig. 1) showed a signiﬁcant shift to the right (higher EC50)
for the resistant compared with the susceptible isolate. All EC50
values including the conﬁdence limits and the RR values, reﬂecting
signiﬁcant differences in the EC50 are shown in Table 1. IVM and
the two milbemycins (Mil A3 and Mil A4) were the most potent
(EC50 = 0.364–0.752 nM) for H. contortus. Interestingly, the two
components of IVM, IVM B1a and IVM B1b, were less potent
(0.950 nM) than the mixture. MOX was similar in potency to
IVM B1a and IVM B1b. MOX had the lowest ranked RR (2.4), fol-
lowed by IVM B1a, IVM B1b, IVM and the other two milbemycins.
Compared with H. contortus, the drugs were about 10-fold less
potent (i.e. EC50 was 10-fold higher) in T. colubriformis. With
T. colubriformis, there was little difference between the potency
of drugs for the susceptible isolate (EC50 = 3.5–8.5 nM). The most
potent drug was IVM B1a (EC50 = 3.54 nM), the least potent Mil
A3 (EC50 = 8.45 nM). IVM B1b was less potent than IVM B1a and
the potency of IVM was close to the mean of its two components
(Table 1). The shifts in the dose–response curves of resistant iso-
lates (Fig. 2) showed statistically signiﬁcant increases
(p < 0.0001). The milbemycins had the highest ranked RRs (32 for
Mil A3, 29 for Mil A4). In contrast to H. contortus, both components
of IVM showed higher RRs (IVM B1a 15.85 and IVM B1b 12.20)
than IVM itself (9.43). The drug with the lowest ranked RR was
again MOX (RR = 7.26).
For O. circumcincta, the drugs were of similar potency as for
T. colubriformis with EC50 values within the range 1.5–6 nM
(Table 1) (Fig. 3). The most potent drug was Mil A4 followed, in
rank order, by Mil A3, IVM B1a and IVM B1b. IVM itself was less
potent than each of its components. MOX had similar potency as
IVM. The RR’s for Mil A3, IVM B1a and Mil A4 exceeded 4, for
IVM B1b and IVMwere2.5 and MOX was again ranked the lowest
with RR of 1.13 which was not signiﬁcant.3.2. Larval migration inhibition assay
During incubation, larvae underwent transient paralysis, abate-
ment of paralysis and, by 18 h, irreversible paralysis. As a result,
reproducible migration performance was obtained for all speciesfollowing 24 h of migration. Selected dose response curves high-
lighting the differences between IVM and MOX for H. contortus
and O. circumcincta are shown in Fig. 4 and the data in Table 2.
For H. contortus, the most potent drug was MOX with an EC50 of
371 nM. The three ivermectins ranged between 502 and 676 nM,
followed by Mil A4 and Mil A3. The two components of IVM both
ranked more highly than IVM itself and both milbemycins were
less potent again (Table 2).
For H. contortus, MOX was the only drug for which a signiﬁcant
difference (RR = 6.74) was obtained. For Mil A3 and A4 RRs were
not calculated due to lack of ﬁt. Selected dose response curves
for T. colubriformis highlighting the differences between IVM and
its two components are shown in Fig. 5. Here, the most potent
drugs were IVM and MOX, followed by IVM B1b and IVM B1a
and then the two milbemycins. In contrast to H. contortus, both
components of IVM were less potent than IVM itself (Fig. 5;
Table 2). For T. colubriformis, shifts in the dose response curves
and signiﬁcant RRs were observed for all drugs tested. MOX and
IVM B1b furnished similar RRs.
For O. circumcincta, IVM (EC50 = 266 nM) was ranked as the
most potent drug although both of its components were relatively
less potent (472–514 nM) (Table 2). Of the three milbemycins,
MOX was the highest ranked (EC50 = 618 nM). For RRs, signiﬁcant
differences in EC50 values between susceptible and resistant iso-
lates were obtained for all but Mil A4 and the RR for MOX was
ranked highest at 22.45.4. Discussion
4.1. Parasite isolates and assays
Using a matrix of chemicals, assays and species provided valu-
able data on resistance pharmacology. Some differences that were
observed between the species and their isolates may reﬂect histo-
ries of selection for resistance as well as inherent species differ-
ences in drug action and resistance. For example, while all three
resistant isolates were IVM-resistant, only the T. colubriformis
and O. circumcincta isolates were also MOX-resistant. Although
the isolates used here may not be representative of ﬁeld isolates,
their high levels of resistance meant they were good tools for
investigating the pharmacology of ML resistance because they pro-
vided clear contrasts in the assay results.
While the study of free-living stages has many costs, logistic
and ethical advantages over in vivo tests, such in vitro assays are
surrogates for adult parasites which are the target of anthelmintic
control. Eggs and larval stages will likely differ from adults in many
ways, such as expressing different biochemical sites, different (or
no) resistance mechanisms and possible physicochemical differ-
ences in drug exposure. Nevertheless, these assays have proved
useful in measuring ML resistance and mirror aspects of the resis-
tance pharmacology seen in adult worms while removing the inﬂu-
ence of drug pharmacokinetics in vivo. Further, in vitro assays are
amenable to ﬁtting concentration/response curves and thus statis-
tical analysis. The two assays chosen for this study have the advan-
tage that they are widely used and comparable to other studies.
While other assays such as the larval feeding inhibition assay
(Bartley et al., 2009) may have revealed activity speciﬁcally at
the pharyngeal site, this assay has not furnished signiﬁcant differ-
ences between ML susceptible and resistant isolates and it was
therefore not used.
Avermectins and milbemycins are potent inhibitors of develop-
ment of larvae in the low nM range for H. contortus, T. colubriformis
and O. circumcincta (Table 1). The present data show similar EC50
values to previous studies using IVM in development assays
(Giordano et al., 1988; Lacey et al., 1990; Taylor, 1990; Hubert
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Fig. 1. Activity of tested drugs (A: IVM B1a, B: IVM B1b; C: IVM; D: Mil A3; E: Mil A4; F: MOX) as inhibitors of larval development of susceptible versus resistant Haemonchus
contortus isolates (H.c. McM, H.c. CAVR) in the larval development assay (LDA).
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been measured previously. The RRs in the present study clearly
discriminate susceptible from resistant isolates and all but one of
the drug/species comparisons are signiﬁcant (Table 1).
Like previous studies on contraction and motility (Gill and
Lacey, 1993; Kotze et al., 2006) our data show effects in the
LMIA in the uM range. This assay relies on the ability of MLs
to inhibit body muscle contraction and worm movementrequired for larvae to negotiate the sieve or move under obser-
vation. This was conﬁrmed by observations that migrating
worms were motile and those not migrating moved slowly or
not at all or assumed angular postures and performed jerky
movements consistent with the observations of larvae (Gill and
Lacey, 1993) and adult H. contortus (Geary et al., 1993). In
contrast, IVM and MOX inhibited locomotion but not velocity
in Caenorhabditis elegans (Ardelli et al., 2009).
Table 1
EC50 (effective concentration for 50% inhibition) with 95% conﬁdence limits (CL) in nM and the resistance ratios (RR) for the tested macrocyclic lactones in the LDA for susceptible
and resistant isolates of Haemonchus contortus (H.c. McM, H.c. CAVR), Trichostrongylus colubriformis (T.c. McM, T.c. MOX-R) and Ostertagia circumcincta (O.c. McM, O.c. WAMIRO).
Drugs H.c. McM H.c. CAVR RR p T.c. McM T.c. MOX-R RR p O.c. McM O.c. WAMIRO RR p
EC50 (CL) EC50 (CL) EC50 (CL) EC50 (CL) EC50 (CL) EC50 (CL)
B1a 0.913 (0.75–1.11) 2.83 (2.42–3.31) 3.10 * 3.54 (3.09–4.04) 56.1 (47.42–66.31) 15.85 * 3.59 (3.47–4.23) 15.1 (10.31–22.23) 4.21 *
B1b 0.996 (0.73–1.36) 3.35 (3.01–3.73) 3.38 * 6.76 (6.25–7.31) 82.5 (64.14–106.1) 12.20 * 3.62 (2.92–4.49) 8.96 (7.577–10.59) 2.48 *
IVM 0.635 (0.49–0.83) 4.21 (3.74–4.73) 6.63 * 5.57 (4.99–6.22) 52.5 (44.64–61.64) 9.43 * 5.58 (5.06–6.16) 14.3 (10.87–18.85) 2.56 *
MOX 0.965 (0.62–1.49) 2.33 (2.07–2.62) 2.42 * 7.00 (5.70–8.59) 50.8 (41.81–61.60) 7.26 * 5.04 (4.69–5.40) 5.71 (4.67–6.99) 1.13
Mil A3 0.752 (0.68–0.83) 6.50 (5.96–7.10) 8.64 * 8.45 (5.94–12.02) 271 (215.9–339.4) 32.07 * 3.56 (2.71–4.68) 14.7 (12.68–16.3) 4.13 *
Mil A4 0.364 (0.34–0.39) 3.40 (3.00–3.85) 9.34 * 4.25 (3.58–5.06) 123 (108.4–139.4) 28.94 * 1.77 (1.33–2.36) 7.09 (5.54–9.07) 4.01 *
* p < 0.0001.
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Fig. 2. Activity of tested drugs (A: IVM B1a, B: IVM B1b; C: IVM; D: Mil A3; E: Mil A4; F: MOX) as inhibitors of larval development of susceptible versus resistant
Trichostrongylus colubriformis isolates (T.c. McM, T.c. MOXR) in the larval development assay (LDA).
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Fig. 3. Activity of tested drugs (A: IVM B1a, B: IVM B1b; C: IVM; D: Mil A3; E: Mil A4; F: MOX) as inhibitors of larval development of susceptible versus resistant Ostertagia
circumcincta isolates (O.c. McM, O.c. WAMIRO) in the larval development assay (LDA).
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species (although two could not be ﬁtted for statistical compari-
sons, Table 2). In general, the milbemycins (A3, A4) had poor po-
tency (EC50s near 1 lM) while the related drug MOX was the
most potent and also generated the highest RRs in H. contortus
and O. circumcincta Larvae of H. contortus were also studied by
Kotze et al. (2006). Although that work differed from ours in using
an agar overlay on the migration sieve, results were similar, with
the one point of direct comparison with that study being our
EC50 value of 755 nM IVM with the published value of 1.87 lg/ml
(2150 nM) (Kotze et al., 2006). While Geary et al. (1993) reported
that IVM inhibited motility in adult H. contortus at >10nM, Kotze
et al. (2012), using observational techniques, reported inhibitionby ABA at 0.015 nM. The relevance of subtle motility effects on par-
asite expulsion are not known, but the data do argue for the muscle
site as a potent site of action and resistance of the MLs.
4.2. Effects on parasite species
In both assays, the potency differences between IVM and MOX
are least marked for T. colubriformis and the RR values also accord
(7.26 versus 7.28). These data, together with the in vivo phenotype
of IVM and MOX resistance for T.c. MOX-R, suggest that the drug
receptors present in the two assays are similar and that resistance
occurs by a similar mechanism. The 100-fold differences in po-
tency between the assays may relate to the sensitivity of detection
A B
C
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
10
20
30
40
50
60
70
80
90
100
H.c. McM
H.c. CAVR
IVM in M [log]
)
%( eavral detargi
m-no
N H.c. McM
H.c. CAVR
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
10
20
30
40
50
60
70
80
90
100
MOX in M [log]
)
%( eavral detargi
m-no
N
D
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
10
20
30
40
50
60
70
80
90
100
MOX in M [log]
)
%( eavral detargi
m-no
N O.c. McM
O.c. WAMIRO
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
10
20
30
40
50
60
70
80
90
100
O.c. McM
O.c. WAMIRO
IVM in M [log]
)
%( eavral detargi
m-no
N
Fig. 4. Activity of IVM and MOX as inhibitors of larval migration of susceptible versus resistant isolates of Haemonchus contortus (H.c. McM, H.c. CAVR) and Ostertagia
circumcincta (O.c. McM, O.c. WAMIRO) in the larval migration inhibition assay (LMIA).
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assay.WhyML-resistance in T. colubriformis has different character-
istics to the other two species is not known. ML-resistance is rela-
tively rare in T. colubriformis compared with the other two species
suggesting that a different resistance mechanismmay be operating
compared with the other species. Because this isolate has a high le-
vel of resistance and a simple resistance pharmacology, it provides a
useful model for exploring what might be a single mechanism.
For H. contortus, IVM and MOX have similar potency in each as-
say and values are 100–1000-fold less sensitive in the LMIA com-
pared with the LDA. IVM has a marginally higher RR in the LDA
(2-fold) but the RR for MOX is 6-fold higher in the LMIA. These data
suggest that the two drugs share receptors in Haemonchus but the
RRs suggest that IVM-resistance occurs at the sites present in the
LDA and MOX resistance occurs at sites in the LMIA. For O. circum-
cincta, IVM and MOX are equipotent in the LDA, both with low RRs.
In contrast, MOX is signiﬁcantly less potent in the LMIA, but has a
large RR. Research performed by Sutherland et al. (2002) suggests a
genetic basis for differences between resistance to IVM andMOX in
an isolate of O. circumcincta in vivo. These workers claim that IVM
resistance is dominant and MOX resistance is semi-dominant. Le
Jambre et al. (2005) draw similar conclusions for a H. contortus iso-
late. Together, these data suggest that a different or additional ge-
netic mechanism is at play in MOX resistance compared with IVM
resistance. In terms of diagnosis, these observations suggest that
the LMIA may be a superior tool for ﬁeld monitoring of resistance
to MOX especially for detecting emerging MOX resistance. If this is
true, then further selection of the H. contortus CAVR isolate will
lead to MOX resistance.4.3. Effects of analogues
One component of this study was to investigate if the two
chemical components of IVM could account for the action of the
mixture. In the LDA, for each species, IVM potency was of a similar
order to that of its components showing that they share a common
pharmacology in this assay. In the LMIA, IVM and its components
show complex patterns, and the components do not suitably ac-
count for the activity of IVM. Only for T. colubriformis, where de-
tailed comparisons are shown in Fig. 5, do the responses towards
the two components achieve an equivalent effect to IVM. In this
case, resistance appears to be predominantly to IVM B1b, but to-
gether the data do not suggest that the components differ in
receptor site speciﬁcity. As a group, the milbemycins have hetero-
geneous effects. In the LDA, Mil A4 has signiﬁcantly superior po-
tency and the RRs for Mil A3 and Mil A4 are 3-fold higher than
that for MOX. In the LMIA, the reverse is apparent for H. contortus
and O. circumcincta where MOX is most potent and has high RRs
(not statistically tested). Because Mil A3, Mil A4 and IVM appear
to have equivalent effects in both assays and these are distinct
from the effects of MOX it is likely that MOX binds to the same
binding site(s) with different kinetics and/or has additional sites
of action and/or resistance. This is an important ﬁnding in terms
of IVM and MOX resistance. In silicomodels of a putative H. contor-
tus receptor predict that IVM and MOX bind to common domains
but that their various side chains affect binding kinetics. If MOX
behaves differently to the other MLs, including other milbemycins
and IVM, then it follows that the saccharide group, which is a
feature of the ivermectins only, does not account for the unique
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Fig. 5. Activity of IVM and its components IVM B1a and IVM B1b as inhibitors of
larval migration of susceptible versus resistant isolates of Trichostrongylus colubr-
iformis (T.c. McM, T.c. MOXR) in the larval migration inhibition assay (LMIA).
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ique structural components of MOX such as at the C23 and the
C25-associated side chains (see Prichard et al., 2012).
4.4. Sites of action and resistance
In a diagnostic setting, the LDA has the advantage that it can de-
tect the resistance status across several species and anthelmintic
classes. Benzimidazoles and levamisole are known to affect egg
development and larval hatch respectively and their effects are
likely to be independent of the pharynx. The inhibition of develop-
ment by the MLs is claimed to be due to interruption to feeding
(Gill and Lacey, 1998). The evidence cited for this is the equipoten-
cy of the compounds to inhibit pharyngeal activity and
J. Demeler et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 109–118 117development. A site of action for IVM and ABA in the pharynx is
strongly supported by previous studies in larvae, adults (Geary
et al., 1993; Sheriff et al., 2002) and C. elegans, (Dent et al., 2000).
Similarly, development of L1 of C. elegans is affected by IVM and
MOX concentrations of <1 nM and 39 nM, respectively, which are
similar to their effects on pharyngeal pumping (4.9 and 78 nM)
(Ardelli et al., 2009). Although these data are suggestive, it is not
possible to ascribe a site of action for the MLs in this assay, how-
ever, paralysis of the pharynx is likely to be one component con-
tributing to responses in the LDA. It is also clear from the results
of the present study that the LDA and the LMIA measure different
effects presumably at distinct and/or overlapping sites of action.
It has been reported, that isolates resistant to IVM show de-
creased susceptibility to MOX in vivo and in vitro (Conder et al.,
1993; Shoop, 1993; Gill et al., 1995). For some IVM-resistant para-
sites MOX has higher potency in vivo and retains therapeutic efﬁ-
cacy. (Craig et al., 1992; Kieran, 1994; Bartley et al., 2004, 2005).
However, the superior potency of MOX against the CAVR isolate
is not reﬂected in the present results on larvae in vitro where
IVM and MOX are roughly equipotent. This suggests that the drugs
act at similar sites and with similar afﬁnity. Indeed, the LMIA may
be a strong discriminator of MOX resistance that is diminished by
the pharmacokinetic effect in vivo. An explanation for the increased
potency of MOX in vivo thus probably resides in its pharmacokinet-
ics where it has extended clearance kinetics and prolonged interac-
tion with parasites (Hennessy and Alvinerie, 2002). In order to
conﬁrm this and the importance of apparent genetic differences,
the potencies of IVM and MOX need to be compared in adult par-
asites in vitro, including the use of muscle–speciﬁc assays.
Knowledge of the mechanisms of ML resistance remains elusive
and differences in IVM and MOX resistance are difﬁcult to explain.
They may reﬂect differences in their interactions with glutamate-
gated chloride channel receptors (Glu Cl) of nematodes which
are the target of the MLs. For example, biochemical data reveal
quantitative and qualitative differences between IVM and MOX
binding to these receptors (Hejmadi et al., 2000; Wolstenholme
and Rogers, 2005). In addition, putative resistance mechanisms
may be associated with a multiplicity of different genes (Gilleard,
2006). For example, it has been suggested that MLs select parasite
P-glycoproteins and that IVM and MOX interact in different ways
with mammalian Pgps (Prichard et al., 2012). If such differences
are borne out in studies on parasites, this might lead to an under-
standing of mechanisms that modulate ML resistance.Acknowledgements
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